GET DAILY SIGNALSTurn Therapeutics (TTRX): Analyst Views Suggest +68% Upside to $17
Key Takeaways
- The central price target used in this analysis is $17, calculated as the arithmetic mean of four verified, attributable analyst price targets.
- The latest verified market price for Turn Therapeutics (TTRX) is about $10.13, meaning the stock would need to rise roughly 68% to reach the target.
- The analyst price target range is unusually wide, spanning from $8 to $26, reflecting sharp disagreement about the company's clinical and commercial outlook.
- Supporting factors include a proprietary PermaFusion drug-delivery platform, the GX-03 eczema program, and a global partnership with Medline.
- Key risks include a pre-revenue business model, persistent net losses, a very small cash balance, and heavy insider ownership of a thinly traded float.
- For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these additional pages.
- Traders seeking a broader, data-driven perspective can also explore Trending AI Robots.
Reviewing the Analyst Price Targets
Turn Therapeutics Inc. (TTRX) is a clinical-stage biotechnology company listed on the Nasdaq, not an exchange-traded fund. It develops topical and transdermal drug formulations built on its proprietary PermaFusion delivery technology, with its lead candidate GX-03 being studied for moderate-to-severe eczema.
Four current, attributable analyst price targets were reviewed. Jason Kolbert of D. Boral Capital set an $8 target with a Buy rating; Karen Sterling of WBB Securities set a $10 target with a Hold rating; Dev Prasad of Lucid Capital Markets initiated coverage with a $24 target and a Buy rating; and Ladenburg Thalmann initiated with a $26 target and a Buy rating. The average analyst price target across these four figures is $17, with an approximate range of $8 to $26.
That wide range tells an important story. The bullish targets ($24–$26) imply confidence that positive GX-03 clinical data and the Medline partnership can re-rate the shares toward their prior highs. The more cautious figures ($8–$10) reflect skepticism about a pre-revenue company that is still burning cash. The average of these views is a forward-looking reference point, not a guarantee, and it sits well above the current share price. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With the stock near $10.13, reaching the $17 central target implies upside of approximately 68% — a very large move by any standard. TTRX trades well below its 52-week high of $16.45 and far below its all-time high of $26.50 reached in October 2025, but also far above its 52-week low of $2.57.
The path toward a higher price likely runs through clinical milestones rather than current financials. Turn Therapeutics is pre-revenue, posts negative EPS (earnings per share) of about -$0.43 on a trailing basis, and holds only about $10.4 million in cash against roughly $6.2 million in debt. Any sustained re-rating would need to be driven by data readouts, partnership economics, or additional financing on favorable terms rather than near-term earnings growth.
What Could Support a Move Toward the Target
Several verified factors underpin the more optimistic analyst price forecasts. The global supply, development, and license agreement with Medline — one of the largest medical-surgical product distributors — provides commercial reach and potential milestone economics. The GX-03 program addresses a large, underserved dermatology market with a non-systemic, non-biologic topical approach, which could differentiate it from injectable biologics. Insiders own roughly 58% of shares, aligning management with shareholders, and the stock has demonstrated the capacity for sharp rallies, having traded above $16 within the past year.
What Could Prevent the Target From Being Reached
The risks are equally concrete. The company generated no meaningful revenue, reported a net loss of roughly $12.8 million, and has a thin cash runway that may require additional dilutive fundraising. With only two employees and a market capitalization near $309 million, the stock's valuation rests almost entirely on future clinical success. Negative or inconclusive GX-03 trial results, partnership setbacks, or a broader risk-off shift in the biotechnology sector could compress the valuation. The extremely wide analyst range itself signals that the $17 figure is far from a consensus of conviction.
Technical Levels and Market Structure
TTRX shows a durable technical structure defined by a 52-week range of $2.57 to $16.45. The 200-day moving average near $7.20 sits well below the current price, while the 50-day moving average near $11.72 acts as nearer-term resistance. The $16.45 area represents the most recent major resistance level, and a decisive break above it would open the door toward the all-time high of $26.50. On the downside, the $8-to-$10 zone, which coincides with the cautious analyst targets, is a meaningful support level to watch.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month horizon, though individual analysts may differ and no formal horizon was uniformly disclosed. The most relevant upcoming items include GX-03 clinical data readouts, updates on the Medline partnership and any milestone payments, quarterly earnings and cash-position disclosures (the most recent report arrived in early November 2026), and any new analyst initiations or target revisions. Given the company's small cash balance, any announced financing will be closely watched for dilution.
Final Assessment
Can TTRX reach $17? The question hinges on clinical execution rather than current fundamentals. The central target — the arithmetic mean of four verified analyst price targets ranging from $8 to $26 — sits roughly 68% above the latest price, a very large move that would require positive GX-03 data, tangible Medline partnership value, or a substantial re-rating. The bullish analyst cases point to the platform's differentiation and market opportunity; the cautious cases point to a pre-revenue, cash-constrained company. Investors should weigh that disagreement carefully and monitor clinical milestones, cash position, and analyst revisions as the clearest signposts for whether the stock can close the gap toward $17.
Using AI Tools for Ongoing Monitoring
In my research process, I have found Tickeron's AI Daily Buy/Sell Signals to be a practical way to track TTRX alongside thousands of other stocks. The tool applies artificial intelligence to monitor market conditions, technical behavior, and broader trends, producing Buy, Sell, or Hold signals that can complement fundamental analysis of clinical events and partnerships. It helps spot shifts in momentum that might otherwise go unnoticed until later.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TTRX in +7.97% Uptrend, growing for three consecutive days on November 11, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TTRX advanced for three days, in 55 of 61 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 9 of 12 cases where TTRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for TTRX just turned positive on November 11, 2026. Looking at past instances where TTRX's MACD turned positive, the stock continued to rise in 7 of 8 cases over the following month. The odds of a continued upward trend are 88%.
TTRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TTRX as a result. In 15 of 18 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
TTRX moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TTRX crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 1 of 1 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TTRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for TTRX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TTRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TTRX's P/B Ratio (419.116) is very high in comparison to the industry average of (3.498). P/E Ratio (-33.435) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TTRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement